Given the clear estrogenic nature of certain prostate tumors, the use of aromatase inhibitors and SERMs as an endocrine therapy for prostate cancer has been proposed since a long time ago [69,70]. The gene discussed is CYP19A1; the disease is Familial prostate cancer.